Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
This article was originally published in The Pink Sheet Daily
Executive Summary
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."
You may also be interested in...
Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner
Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board
Best of the Blog: IN VIVO, September 2009
Our favorite posts from The IN VIVO Blog about issues not covered elsewhere in this month's IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).
Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner
Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board